Inhibition of intestinal microflora β-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats

Cancer Chemotherapy and Pharmacology

Volumn 42, Issue 4, 1998, Pages 280-286

  Takasuna, Kiyoshi ^a   Hagiwara, Takehiro ^a   Hirohashi, Masaaki ^a   Kato, Michiyuki ^a   Nomura, Mamoru ^a   Nagai, Eiichi ^a   Yokoi, Tsuyoshi ^b,c   Kamataki, Tetsuya ^b  

^a DAIICHI SANKYO CO   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

^c KANAZAWA UNIVERSITY   (Japan)

Author keywords

Glucuronidase; CPT 11; Diarrhea; SN 38; SN 38 glucuronide

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; BETA GLUCURONIDASE; GLUCURONIDE; IRINOTECAN; PENICILLIN G; STREPTOMYCIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG GLUCURONIDATION; DRUG METABOLISM; DRUG TISSUE LEVEL; ENZYME ACTIVITY; GASTROINTESTINAL TOXICITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTESTINE; INTESTINE FLORA; INTRAVENOUS DRUG ADMINISTRATION; LARGE INTESTINE; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; BACTERIA; CAMPTOTHECIN; DIARRHEA; ENZYME INHIBITORS; GLUCURONIDASE; INJECTIONS, INTRAVENOUS; INTESTINE, LARGE; INTESTINE, SMALL; MALE; PENICILLINS; RATS; RATS, WISTAR; STREPTOMYCIN;

EID: 0031827877     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050818     Document Type: Article

References (26)

1. Abigerges D, Armand JP, Chabot GG, Da Costa L, Fadel E, Cote C, Hérait P, Gandia D (1994) Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J Natl Cancer Inst 86: 446
2. Abigerges D, Chabot GG, Armand JP, Herait P, Gouyette A, Gandia D (1995) Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 13: 210
3. Araki E, Ishikawa M, Iigo M, Koide T, Itabashi M, Hoshi A (1993) Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11. Jpn J Cancer Res 84-697
4. Atsumi R, Suzuki W, Hakusui H (1991) Identification of the metabolites of irinotecan, a new derivative of camptothecin, in rat bile and its biliary excretion. Xenobiotica 21: 1159
5. Conti JA, Kemeny NE, Saltz LB, Tong WP, Chou TC, Sun M, Pulliam S, Gonzalez C (1996) Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 14: 709
6. Fukuoka M, Niitani H, Suzuki A, Motomiya M, Hasegawa K, Nishiwaki Y, Kuriyama T, Ariyoshi Y, Negoro S, Massuda N, Nakajima S, Taguchi T (1992) A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol 10: 16
7. Gupta E, Lestingi TM, Mick R, Ramirez J, Yokes EE, Ratain MJ (1994) Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res 54: 3723
8. Kaneda N, Yokokura T (1990) Nonlinear pharmacokinetics of CPT-11 in rats. Cancer Res 50: 1721
9. Kaneda N, Nagata H, Furuta T, Yokokura T (1990) Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res 50: 1715
10. Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K (1991) Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 51: 4187
11. Kudoh S, Fukuoka M, Masuda M, Kusunoki Y, Matsui K, Negoro S, Takifuji N, Nakagawa K, Hirashima T, Tamanoi M, Nitta T, Yana H, Takada M (1993) Relationship between CPT-11 pharmacokinetics and diarrhea in the combination chemotherapy of irinotecan (CPT-11) and cisplatin (CDDP). Proc Am Soc Clin Oncol 12: 141
12. Lokiec F, Canal P, Gay C, Chatelut E, Armand JP, Roché H, Bugat R, Goncalvés E, Mathieu-Boue A (1995) Pharmacokinetics of irinotecan and its metabolites in human blood, bile, and urine. Cancer Chemother Pharmacol 36: 79
13. Masuda N, Fukuoka M, Kudoh S, Kusunoki Y, Matsui K, Takifuji N, Nakagawa K, Tamanoi M, Nitta T, Hirashima T, Negoro S, Takada M (1993) Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer. Br J Cancer 68: 777
14. Masuda N, Fukuoka M, Kudoh S, Kusunoki Y, Matsui K, Nakazawa K, Hirashima T, Tamanoi M, Nitta T, Yano T, Negoro S, Takifuji N, Takada M (1994) Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer. J Clin Oncol 12: 90
15. Ohe Y, Sasaki Y, Shinkai T, Eguchi K, Tamura T, Kojima A, Kunikane H, Okamoto H, Karato A, Ohmatsu H, Kanazawa F, Saijo N (1992) Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion. J Natl Cancer Inst 84: 972
16. Rivory LP, Robert J (1995) Identification and kinetics of a β-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan. Cancer Chemother Pharmacol 36: 176
17. Rothenberg ML, Kuhn J, Burris HA, Morales MT, Nelson J, Eckardt JR, Rock MK, Terada K, Von Hoff DD (1992) A phase I and pharmacotrial of CPT-11 in patients with refractory solid tumors. Proc Am Soc Clin Oncol 11: 113
18. Rothenberg ML, Kuhn JG, Burris III HA, Nelson J, Eckardt JR, Tristan-Morales M, Hilsenbeck SG, Weiss GR, Smith LS, Rodriguez GI, Rock MK, Von Hoff DD (1993) Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol 11: 2194
19. Rothenberg ML, Eckardt JR, Kuhn JG, Burris III HA, Nelson J, Hilsenbeck SG, Rodriguez GI, Thurman AM, Smith LS, Eckhardt SG, Weiss GR, Elfring GL, Rinaldi DA, Schaaf LJ, Von Hoff DD (1996) Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 14: 1128
20. Rougier P, Bugat R, Douillard JY, Culine S, Suc E, Brunet P, Becouarn Y, Ychou M, Marty M, Extra JM, Bonneterre J, Adenis A, Seitz JF, Ganem G, Namer M, Conroy T, Negrier S, Merrouche Y, Burki M, Mousseau M, Herait P, Mahjoubi M (1997) Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 15:251
21. - secretion induced by the antitumor drug, irinotecan (CPT-11), in the rat colon. Naunyn Schmiedehergs Arch Pharmacol 351: 309
22. Sasaki Y, Hakusui H, Mizuno S, Morita M, Miya T, Eguchi K, Shinkai T, Tumura T, Ohe Y, Saijo N (1995) A pharmacokinetic and pharmacodynamic analysis of CPT-11 and its active metabolite SN-38. Jpn J Cancer Res 86: 101
23. Takasuna K, Kasai Y, Kitano Y, Mori K, Kakihata K, Hirohashi M, Nomura M (1995) Study on the mechanisms of diarrhea induced by a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats (in Japanese). Folia Pharmacol Jpn 105: 447
24. Takasuna K, Kasai Y, Kitano Y, Mori K, Kobayashi R, Hagiwara T, Kakihata K, Hirohashi M, Nomura M, Nagai E, Kamataki T (1995) Protective effects of Kampo medicines and baicalin against the intestinal toxicity of a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats. Jpn J Cancer Res 86: 978
25. Takasuna K, Hagiwara T, Hirohashi M, Michiyuki K, Nomura M, Nagai E, Yokoi T, Kamataki T (1996) Involvement of β-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res 56: 3752
26. Videla S, Vilaseca J, Guarner F, Salas A, Trcserra F, Crespo E, Antolin M, Malagelada J-R (1994) Role of intestinal microflora in chronic inflammation and ulceration of the rat colon. Gut 35: 1090